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Introduction
“I started my career wanting to learn about the structural basis and 
cell mechanics of insulin secretion and ended it trying to cure diabe-
tes with islet transplantation. Gosh, what a surprising turn a life in 
science can take!” (Paul Lacy, September 1987).
Throughout his academic career at Washington University, 
from the early 1950s, as a newly minted Assistant Professor of 
Pathology, to the mid 1990s, when he retired as Kroc Professor of 
Pathology after a prior long term as departmental chairman, the 
late Paul Lacy had a focused, “islet-centric” scientific interest.1 
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He wished to learn as much as he could about the function, espe-
cially insulin secretion, of the pancreatic islet of Langerhans. In 
the first phase of that career (1955–1973), he studied the intricate 
in situ ultrastructure and in vitro function of the islet. He made 
a major contribution towards characterizing the substructure of 
component a, b and d cells by techniques including selective 
staining and secretagogue-induced granule depletion. He identi-
fied granule “emiocytosis” (exocytosis) as the key mechanism 
of hormone exit from islet cells. In addition, he recognized the 
importance of granule maturation and movement as well as Ca2+ 
entry and the cytoskeleton in the exocytotic process. In doing 
this he provided a first working model for biphasic insulin secre-
tion. Moreover, his development of the isolated islet preparation 
made possible detailed enzymology, electrophysiology and living 
tissue microscopy.
In the second phase of his career (1973–1995), Lacy mounted 
an all-out scientific mission. In a heroic bench-to-bedside effort 
“to cure diabetes mellitus in man by human islet transplanta-
tion,” he developed and disseminated key techniques of human 
islet purification from cadaver donors and subsequent portal 
vein infusion into recipients. His specific aim was “to harvest 
as many pancreatic islets of Langerhans as possible, keep them 
healthy, make them non-antigenic, and then, by golly to trans-
plant them into a safe space in the body,” where they’d “take up 
root,” “appropriately secrete insulin after a meal” and “substitute 
for the sick islets of the diabetic pancreas that couldn’t.” With 
glucose-sensitive islets secreting insulin on a moment-to-moment 
basis “the highs and lows of blood sugar and the end-organ dam-
age of diabetes seen after years of diabetes would be prevented.” 
This work culminated in the first trials of clinical trials of islet 
transplantation in 1990. By articulating this goal with a magical 
presence, a combination of a folksy Midwestern grandiloquence 
and a twinkle in his eye that assured even the casual listener of 
a self-evident truth, he raised awareness, hope and funding for 
a simple and elegant approach at organ replacement. However, 
privately, he remained keenly aware of the Achilles heel of this 
endeavor, namely the need for immunosuppression, the uncer-
tainty of tissue supply and quality, and the potentially unsustain-
able function of islets in a foreign environment. From the early 
1990s until his retirement from active science at Washington 
University in 1995 to pursue a love of archeology, Lacy with 
Over the past three decades the pancreatic islet of 
Langerhans has taken center stage as an endocrine micro-
organ whose glucoregulatory function is highly explicable 
on the basis of the increasingly well understood activities 
of three highly interactive secretory cells. islet dysfunction 
underlies both type 1 and type 2 diabetes mellitus (DM); its 
protection from immune attack and gluco-and lipo-toxicity 
may prevent the development of DM; and its replacement 
by non-surgical transplantation may be curative of DM. 
During a career marked by vision, focus and tenacity, Paul 
Lacy contributed substantially to the development of 
each of these concepts. in this review we focus on Lacy’s 
contribution to the development of the concept of the 
islet as a micro-organ, how this foreshadowed our current 
detailed understanding of single cell function and cell-cell 
interactions and how this led to a reduced model of islet 
function encouraging islet transplantation. Next, we examine 
how clinical allotransplantation, first undertaken by Lacy, has 
contributed to a more complex view of the interaction of islet 
endocrine cells with its circulation and neighboring tissues, 
both “in situ” and after transplantation. Lastly, we consider 
recent developments in some alternative approaches to 
treatment of DM that Lacy could glimpse on the horizon but 
did not have the chance to participate in.
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cytosolic components, especially insulin granules,4 could not 
have come at a more propitious time. Insulin was being rou-
tinely and reliably measured by radioimmunoassay. In addition, 
the rudiments of a general hypothesis for stimulus-secretion 
coupling in b-cells were being established through several 
approaches. Ashcroft and Randle in Oxford and Matschinsky 
and group in St. Louis were providing strong evidence that glu-





were essential for stimulation of insulin secretion and biosynthe-
sis.5 Grodsky and colleagues,6,7 investigating secretion of insu-
lin by the perfused pancreas into the hepatic vein, had already 
shown that insulin release in response to a sustained rise in 
glucose was biphasic and that both phases required aerobic oxi-
dation of glucose and adequate concentrations of extracellular 
Ca2+. Dean and Matthews8 using microdissected islets, demon-
strated that islet cells responded to a rise in ambient glucose by 
depolarizing and then firing action potentials whose upstrokes 
appeared to be dependent on the concentration of extracellu-
lar Ca2+. As b-cell depolarization required glucose metabolism 
and was associated with a decrease in membrane permeability to 
K+, a link between b-cell metabolism and excitability was being 
established. Hence, an outline of a hypothesis of stimulus-secre-
tion coupling in b-cells was emerging: glucose metabolism, by 
changing cell energetics was promoting electrical activity, which 
in turn was promoting Ca2+ entry and Ca2+-dependent exocyto-
sis of insulin granules.
Work using all of these approaches was now made immensely 
easier and more disseminatable by the technique for mass iso-
lation of islets. Lacy’s lab, which had previously published a 
host of electron microscopic images of maturation and “emio-
cytosis” (surface rupture and shower-like release of contents of 
insulin granules in fixed tissue), demonstrated in monolayers of 
cultured islets that granules, in constant motion, preferentially 
approached the membrane after glucose stimulation; this was 
inhibited after application of agents that disassemble cytoskel-
eton.9,10 On this basis Lacy proposed that biphasic insulin secre-
tion seen with high glucose stimulation (>10 mM) might be 
explained as follows. First phase insulin secretion, unaffected by 
cytoskeletal disrupting agents, might result from the discharge 
of granules already present (in contemporary terminology 
“docked”) at the membrane. In contrast, second phase insulin 
secretion, greatly decreased by cytoskeletal disrupting agents, 
might result from granules moving towards the membrane along 
cytoskeleton as their contents undergo progressive processing 
and aggregation. In contemporary terminology this would be 
while in transit from the Golgi to the plasma membrane, first by 
kinesin motors along microtubules, then penetrating the corti-
cal actin cage aided by myosin V motors, and lastly attaching to 
the membrane via the formation of complexes between vesicle 
(v-, VAMP) and target (t-, SNAP23/25, syntaxin) SNARE pro-
teins. Later experiments demonstrated small oscillatory changes 
in insulin secretion occurring near resting levels of glucose.10a
Within less than a decade of routine availability and dispersion 
of isolated islets, powerful new techniques offered the prospect 
of revolutionizing the entire field of stimulus-secretion coupling 
in endocrine cells. These included: patch clamp recording of 
David Scharp, his long-term partner in the human islet trans-
plantation adventure, concentrated on a variation on the original 
islet transplantation vision, xenotransplanation of much more 
readily available porcine islets after their encapsulation.
To celebrate the legacy of Paul Lacy’s imaginative, tena-
cious, generous and, to be sure, “gutsy” life in science, as well 
as his seminal contributions to the revival of the pancreatic islet 
from relative investigative obscurity, this review shall focus on 
the influence of Lacy’s seminal techniques of islet isolation, his 
exploration of islet function as well as his vision of curative islet 
transplantation. Based on a critical review of the published work 
of Lacy and his contemporaries and two in-depth conversations 
I had with him in 1987 and 2000, I shall concentrate on several 
features. First, how Lacy’s early work on islet function motivated 
cellular and molecular studies of the past two decades that have 
culminated in complex models of stimulus-secretion coupling in 
individual islet cells and as well as produce a “reduced model of 
islet function,” which formed the underlying assumptions of the 
early vision of clinical islet transplantation. Second, how partial 
realization of that vision promoted understanding of pancreatic 
islets as unique micro-organs that maintain a complex internal 
sociobiology, intricate developmental and functional ties with 
their exocrine tissue neighbors, as well as important distant 
interactions with immune surveillance cells, which may be criti-
cal to both autoimmunity of diabetes and islet transplant rejec-
tion. The latter provides an interesting study in how a simple 
idea grows in complexity as it progresses from bench to bedside 
and then back to bench.
Part I: The Islet as a Micro-Organ
Mass isolation of islets and its bonus to physiology, the unrav-
eling of the details of stimulus-secretion coupling in b and a 
cells. Research into the isolation of islets began in the 1960s 
when tens of islets were liberated from rodent pancreas by enzy-
matic (collagenase) incubations of chopped tissue or free hand 
microdissection of surface islets (reviewed in reference 2), both 
usually from obese animals with hypertrophic islets. In a clear 
technical breakthrough, in 1967 Lacy and Kostianovsky3 dem-
onstrated the ability to harvest several hundred metabolically 
active and structurally intact islets from the pancreas of a nor-
mal rat. Prior to digesting the fat-trimmed pancreas with col-
lagenase, they distended and partially disrupted the enveloping 
acini through retrograde injection of physiological saline into 
the cannulated bile/pancreatic duct. The latter maneuver pro-
vided easier access of collagen to the interior of the pancreatic 
tissue. Islets, which are dense ovoid bodies, were separated from 
acini and ductal fragments by gravity sedimentation in a saline-
filled cylinder or by centrifugation in a discontinuous sucrose 
(or later Ficoll) gradient. Using this approach, up to several 
hundred islets could be collected from a rodent pancreas, and 
several thousand islets could be collected from the pancreas of 
large mammal.
Success in harvesting islets and the subsequent ability to dis-
perse these into a preparation of single cells, which could later 
be separated into their component types, or into preparation of 
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and an outer ring of sulfonylurea receptors (SUR 2), interacting 
with the central core in a fashion that binding of MgADP can 
open, while binding of sulfonylureas can, close the Kir-defined 
pore. The closure of K+(ATP) channels, against a background 
of tonically open non-selective cation channels, constitutes the 
basis for cell depolarization (step 4) and the activation of voltage 
dependent Na+, Ca2+ and K+ channels (step 5), which underlie 
complex electrical activity, including trains of large amplitude 
action potentials (APs) or long trains aborted APs riding on pla-
teau potentials. The opening of high voltage activated (HVA) 
Ca2+ channels support rapid entry of Ca2+ (step 6) and Ca2+-
dependent exocytosis of the contents of a small pool (at most 
several hundred) if insulin granules in close proximity to the 
plasma membrane (the readily releasble pool, RRP) (step7) and 
likely recruit granules from more interior regions of the cyto-
plasm into the RRP to refill this pool.20 Individual APs repo-
larize as a result of opening of voltage-dependent K+ channels, 
while plateau depolarizations are likely terminated by the open-
ing of poorly voltage-dependent but Ca2+-activated K+ chan-
nels. Incretin messengers, such glucagon-like intestinal peptide 
(GLP-1) released by enterochromaffin-like (EC) cells of the gut 
epithelium sensing newly digested nutrients, and acetylcholine 
released by stimulation of vagus nerve; both enhance closure of 
K(ATP) channels and help recruit insulin granules into a release 
ready pool.21,22 Current work is focusing on the contributions of 
distinct electrical activity patterns, novel Ca2+ currents, glucose-
derived second messengers other than ATP, and distinct subsets 
of the RRP pools, including a low Ca2+ sensitivity immediately 
releasable pool (IRP) likely docked near clusters of Ca2+ chan-
nels and a high Ca2+ sensitivity (HCSP) likely farther from the 
clusters of Ca2+ channels, to the shaping of biphasic insulin 
secretion.23-26
single channel and whole cell currents underlying both the rest-
ing potential at basal levels of glucose and the complex electri-
cal activity initiated by stimulatory glucose concentrations;11,12 
optical monitoring of metabolic processes including mitochon-
drial membrane potential and free cytosolic ion concentration 
with membrane permeant fluorescent probes;13 and cloning of 
key transporter proteins including the ATP sensitive K chan-
nel.14 Ultimately they also included real time, single cell assays 
of single cell exocytosis. Most prominent among these were the 
following: (1) electrical measurements of increases in membrane 
capacitance (C
m
) proportional to plasma membrane surface area 
in patch clamped cells, indicating increases in plasma mem-
brane surface area due to fusion of organelles the size of insu-
lin granules with the plasma membrane;15,16 (2) electrochemical 
measurements, by oxidation or reduction of discharged of both 
native hormone (insulin) and preloaded false transmitter (sero-
tonin) contents17-19 of exocytosing granules, using carbon fiber 
electrodes whose tips are positioned at the surface of cells, over 
time courses very similar to the increases in C
m
; and (3) optical 
tracking of granules with fluorescent labeled granule contents or 
intramembrane proteins as they approach the plasma membrane 
and fuse with it.
An overall consensus scheme for stimulus-secretion cou-
pling in b-cells is presented in Figure 1A. A rise in serum 
glucose from a baseline level of 3 mM to stimulatory levels of 
5–6 mM enhances glucose import via a moderate affinity transporter 
(glut-2) followed by shunting into glycolysis by glucokinase and 
mitochondrial oxidation (step 1), results in a small rise in cytosolic 
ATP and a fall in cytosolic ADP (step 2) sufficient to close down 
ATP-dependent K-selective ion channels (step 3). The latter con-
sist of an inner ring of four inward rectifier K channel subunits 
(Kir 6.2), encompassing a pore closed by the binding of ATP, 
Figure 1. Proposed schemes of stimulus-secretion coupling in b- and a-cells of the islet. (A) Stimulus-secretion coupling in β-cells. Digestion of food in 
the gut both increases blood glucose and releases incretins (acetylcholine and glucagon-like intestinal peptide), which trigger insulin secretion. GLP-1 
via a G-protein coupled receptor stimulates the production of cAMP which serves to activate protein kinase A or epac, while acetylcholine activates 
via a G-protein coupled muscarinic receptor of CaM kinase ii. (B) Stimulus-secretion coupling in a-cells. A rise in serum glucose and release of con-
tents of insulin granule inhibits glucagon secretion. in contrast, hypoglycemia rapidly stimulates glucagon release by relieving glucose inhibition of 
exocytosis, and by activating central nervous system stress pathways that turn release catecholamines (CA) from adrenergic nerve fibers and adrenal 
medullary chromaffin cells. it is likely that CAs priming the docking of glucagon-containing granules into a readily-releasable pool.
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In addition, secretory products of the b-cell, including GABA, 
Zn2+ as well as insulin, likely suppress glucagon secretion. The 
best studied of these is GABA: it binds to and opens ionotropic 
GABA-A receptor channels, which carry Cl- current and clamp 
the membrane potential of the a-cell near the Cl- equilibrium 
potential thereby reducing a-cells electrical activity and gluca-
gon release. Lastly, at supraphysiological levels of glucose, where 
all remaining K+(ATP) channels are closed, or where large con-
centrations of adrenalin is released by the chromaffin cells of 
the adrenal medulla, HVA Ca2+ channels are augmented, a-cells 
may develop plateau depolarizations to -20 mV (step 5a) that are 
sufficient to tonically activate HVA Ca2+ channels and induce 
Ca2+ entry (step 6a) as well as recruit more granules into a readily 
releasable pool, thereby promoting a phase of glucagon release 
(step 7a), such as that seen during diabetic ketoacidosis or other 
systemic stresses.
Much less is known about stimulus-secretion coupling in 
somatostatin secreting d cells. Early reports (e.g., a recent one 
using human cells) suggest that the resting membrane poten-
tial is dependent on sulfonylurea- but not glucose-dependent 
K+(ATP) channels, that closure of the latter channels sets off 
Na+ and Ca2+ dependent action potentials, and that exocytosis 
is Ca2+ entry-dependent but slow to start and continuing for 
up to a second after current through HVA Ca2+ channnels has 
ceased.35
The extensive effort at understanding the cell biology and 
biophysics of stimulus-secretion coupling underlying normal 
insulin secretion has yielded a better understanding of two rare 
conditions congenital conditions.36-38 Congenital hyperinsu-
linemia of infancy is now thought most often to be due to the 
loss of function mutation of K+(ATP) channels (hyposensitiv-
ity to MgADP). In contrast, neonatal diabetes, is now thought 
most often to be due to gain of function K+(ATP) channels 
(mutations of Kir6.2). However, the rather prevalent state of dis-
ordered insulin secretion in man, type 2 diabetes mellitus (DM 
2) where b-cells of islets, though reduced in number, remain 
largely intact, has been much less tractable. Some evidence sug-
gests that in DM 2 b-cells have underlying variations in key 
coupling factors in cell metabolism (e.g., glucokinase) or key 
channel subunits e.g., SUR of K+(ATP). Other evidence suggests 
that increases in free fatty acids (ffas), resulting from developing 
obesity, may downregulate key regulatory features or even disso-
ciate Ca2+ channels from secretory granules.39 However, to date, 
there has been no systematic study of glucose-induced depolar-
ization, electrical activity or exocytosis in single cells from DM 
2 islets. It is likely that progress will continue to be slow. DM 2 
pancreases are not easily procured and often do not readily yield 
their islets. Also, in a disease that progresses slowly, major het-
erogeneity in basic defects underlying pathophysiology, may be 
present and superimposed on ageing-dependent “loss of vigor” 
of key regulatory features. Lastly, as we have learned from type 1 
DM, even the most promising of small animal models may not 
really replicate the human disease.40 However, investigation may 
be facilitated by cryopreservation/thaw of islets, which preserves 
whole islet and single cell function, to promote storage, sharing 
and comparative testing of available tissue.41
Recently, Lacy’s early experiments on movement of insulin 
granules have attracted intense interest. These approaches have 
been improved and made more quantitative using enhanced 
optical techniques (including evanescent wave or total internal 
reflectance microscopy, confocal microscopy and two photon 
excitation microscopy) for tracking the movement of near mem-
brane granules up to the membrane and their subsequent fusion 
with the plasma membrane and release of their into the extra-
cellular space (ECS). Specific tags for exocytosis include red or 
green fluorescent protein labeled peptides, including C-peptide 
of derived from pro-insulin, intrinsic granule membrane pro-
teins (syncollin, or phogrin), granule membrane attached pro-
teins (tissue plasminogen activator), and even insulin bound 
Zn2+ released into the ECS with decondensation of crystalline 
insulin granule core and then detected by a bath applied fluores-
cent indicator.27-31 Endocytosis can be tracked by the filling of 
granule exocytotic figures with otherwise excluded fluorescent 
dextran, applied as a fluid phase tracer or with quenching of 
pH-sensitive fluorescence on granule re-acidification after their 
recapture. With simultaneous capacitance and amperometry 
recordings from the same cell it is becoming possible to ask what 
fraction of attempted exocytoses lead to exit of the crystalline 
insulin (with its associated Zn2+) into the extracellular space, 
as opposed to more transient and restricted fusion pore forma-
tion with diffusion of more soluble contents, including peptides 
such as C-peptide or small molecular weight molecules such 
ATP and GABA.32 The latter two likely play autocrine or para-
crine regulatory roles in the islet rather than true endocrine roles 
systemically. As anticipated by Lacy, some evidence suggests 
that “newcomer” granules, perhaps refilling the HCSP, are the 
major contributors to second phase insulin secretion. Careful 
application of these approaches may yield evidence as to whether 
granules from distinct granule pools differentially release soluble 
vs. condensed contents, and how rapidly granule membrane is 
retrieved and resorted.30,31
In addition, stimulus-secretion coupling by a-cells has also 
received intensive study using single cell techniques presented 
above. Outlines have emerged as to how tonic glucagon secre-
tion results at very low levels of glucose and insulin, how glu-
cagon secretion is curtailed in response to a post-prandial rise 
in glucose and how glucagon secretion reappears at high levels 
of glucose or in the presence of high concentrations of adren-
alin.32-34 As shown in Figure 1B, a-cells exhibit similar K+(ATP) 
channels as found in b-cells, though most are closed at low levels 
of glucose. In addition, they have an abundance of non-selec-
tive cation channels, as well as standard voltage dependent Na+ 
channels and low voltage activated (LVA or T-type) Ca2+ chan-
nels. At 2–3 mM glucose a-cells are depolarized and fire spon-
taneous action potentials that trigger Ca2+ entry through LVA 
Ca2+ channels; as a result, they exocytose glucagon-containing 
granules. Raising extracellular glucose towards or above 5 mM 
closes down more K+(ATP) channels (step 1–3) and further 
depolarizes the a-cells into a voltage range (near -35 mV) (step 
4) where Na+ and T-type Ca2+ channels are inactivated (step 5) 
and AP amplitude is decreased or its activity even ceases, thereby 
reducing Ca2+ entry (step 6) and glucagon granule exocytosis. 
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ultimately presented on MHC Class II sites on these cells, 
while antigen processed in the proteosome pathway is presented 
on MHC class I. Surface antigen presentation converts imma-
ture, tolerogenic DC/MΦs to mature immunogenic DC/MΦs. 
After migration to local lymph nodes, mature DC/MΦs, via 
their liganded MHC class II sites and co-stimulatory sites bind 
to clonally selected sentinel (CD4+) T-helper (TH) cells, which 
express on their surface T-cell receptors (TCR) for MHC class 
I-peptide complex and co-stimulating molecules. The binding 
of surface T-cell receptors (TCRs) converts members of the TH 
cell population from a largely regulatory to a largely autoreactive 
phenotype (TH1), which begin to divide and secrete inflamma-
tory cytokines, such as IFNγ. In addition, mature DC/MΦs via 
their MHC Class I/peptide complex also to CD8+ cells. The lat-
ter, plus the cytokines secreted by the activated TH1 cells, pro-
mote the maturation of CD8+ cells into cytotoxic T lymphocytes 
(CTLs).
During their circulation, the CD8+-derived CTLs are 
attracted into islets by chemokines released by the local inflam-
matory response to b-cells and as well as by MHC Class I/pep-
tide complexes expressed on the surfaces of b-cells themselves. 
CTL form “immunological synapses” with the b-cells, thereby 
promoting b-cell apoptosis, secondary to release of granzymes 
and channel-forming perforins.
Lacy’s “reduced model of islet function and dysfunction”: 
A bit of oral history concerning some assumptions underlying 
In addition to enhancing our understanding of individual 
endocrine cell types in the islet, studies begun by Lacy, and now 
ongoing world-wide, have demonstrated just how interrelated 
cells in the islet micro-organ are. Lacy’s early ultra-structural 
work42 vigorously continued by Orci and collaborators, demon-
strated complex endocrine-endocrine cell and endocrine cell-
endothelial cell contacts implying complex “social interactions” 
of component cells. These include contiguity of b-cells with 
a- and d-cells, inter-b cell gap junctions, structural polariza-
tion of b-cells between capillaries, and alignment of complex 
endothelial cell pores with regions of preferred exocytosis in 
b-cells. Electrophysiological studies have shown that electrical 
coupling of b-cells contribute to their co-ordinated electrical 
activity43 while secretion studies on single b-cells vs. those in 
small clusters have demonstrated the supra-linear augmenta-
tion of secretion resulting from cell-cell coupling. Furthermore, 
studies of the functional islet microvasculature have provided 
evidence for differential perfusion of islets. In many species the 
afferent circulation burrows into the core of the islet, where the 
majority of b- and d-cells reside, and then branches as to return 
to the mantle where the majority of a-cells reside. This ana-
tomical organization should permit b-cell secretions to inhibit 
a-cell secretion of glucagon and d-cell secretion of somatostatin 
to inhibit both a- and b-cells.
Using an idea proposed by Snell in 1957 to explain the delayed 
growth or destruction of weakly antigenic transplanted tumors, 
in the early 1980s Lacy championed the concept of long-distance 
interactions between cells of the islet micro-organ and the immune 
system.44,45 The major immunological players in this interaction 
are (1) immune surveillance cells traversing the islet and recog-
nizing unusual or foreign antigens and (2) immune affector cells 
returning from lymph nodes with instructions to damage or kill 
cells bearing the unusual or foreign antigens. Simply put, Lacy’s 
idea was that presentation of allo- or auto-antigens by the wan-
dering “passenger leukocytes,” now called dendritic cells/macro-
phages (or DC/MΦs) was critical for both autoimmunity of type 
1 diabetes mellitus and islet transplant rejection, respectively. In 
the case of autoimmunity of diabetes, the autoantigens bound 
by the major histocompatibility complex (MHC) at the surface 
of the DC/MΦs were thought to be present at the surface of the 
b-cell. Contemporary candidates range from insulin, to processed 
viral antigens that mimic other b-cells proteins e.g., Coxsackie 
enterovirus antigens mimicking peptides derived from glutamic 
acid decarboxylase (GAD 64), or rotovirus antigens mimick-
ing peptides derived from tyrosine phosphatase Ia (reviewed in 
ref. 46). In the case of islet transplant rejection, the alloantigens 
were thought to be present on the surface of capillaries of the allo-
grafted islet. Ultimately this leads to local activation of specifi-
cally pre-selected cytotoxic lymphocytes (CTLs) in the draining 
lymph nodes causing them to home in on the islets, destroy target 
cells and reduce islet function.
Passenger macrophages have come of age.47 Our cur-
rent understanding is that when new specific antigens appear 
at the surface of foreign capillaries or b-cells undergoing 
destruction, they are taken up and processed by DC/MΦs 
(see Fig. 2). Antigen processed in the lysosomal pathway is 
Figure 2. immune responses evoked by b-cells: concept of passenger 
leukocyte (dendritic cell/macrophage, DC/MΦ) as key intermediary in 
the development of islet autoimmunity and islet transplant rejection. 
See text for discussion. More recent evidence suggests that the homing 
of CTLs specific for insulin results from the presentation of antigen 
(insulin fragments) by endothelial cells.
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Lacy viewed isolated islets, lacking surrounding acinar tissue, 
as potentially poorly antigenic, provided passenger immune cells 
could be removed from islet vasculature and intrinsic endothelial 
cells were lost or replaced by “host” endothelium as functional 
capillary supply was re-hooked. (This assumption has finally 
been tested experimentally and supported.55) Hence, given a 
choice of transplanting a whole pancreas, which required vascu-
lar anastomoses that could immediately clot, as well as complex 
exocrine drainage exocrine draining, vs. transplanting isolated 
islets into accessible site, in his opinion the latter was clearly 
more preferable.
Lastly, Lacy viewed the generalized dysfunction in diabetic 
mellitus from a “b-cell-centric” perspective, one that was not 
nearly as popular before the mid-1990s as it is now. That is, 
if dysglycemia were controlled sufficiently early on most of the 
long-range consequences of diabetes, including retinopathy, 
neuropathy and nephropathy, might be prevented, amelio-
rated or even partially reversed. However, he thought that fine 
regulation of serum glucose could only achieved with a rapid 
feedback-controlled system requiring glucose-recognition by 
the insulin-dispenser emptying directly into the central blood 
stream, where it is needed, rather than into peripheral sites such 
as skin, where it would only be slowly absorbed. Hence for him 
islet transplantation into vasculature, or sites capable of intense 
vascularization, would be the most preferable source of insulin 
administration and the most physiological approach for insulin 
replacement therapy. Since long-term poor glucose control bred 
islet dysfunction, it would be necessary to transplant a full com-
plement (literally a “pancreas’-worth”) of well-functioning islets 
and to have as many of them as possible continue to function for 
as long as possible.
Hence, for Lacy there were three essential prerequisites for 
islet transplantation. By the late 1980s good progress had been 
made towards satisfying at least two of these.
(1) “Islet greediness” or the efficient harvest, in minimally isch-
emic fashion, as many islets as possible from a donor pancreas and 
then “keeping as many as possible, as happy as possible, for as long as 
possible.” In the case of “islet harvest” from large animal pancre-
ases, the solution was an ingenious bipartite isolation perfusion 
chamber designed by post-doctoral fellow Camillo Ricordi56 
in to which the enzyme-infused pancreas was placed. By 1988, 
Ricordi, Scharp and Lacy were able to isolate as many as 800,000 
islet equivalent from pancreatic of brain-dead human donors and 
nearly 400,000 islet equivalents from canine and pig pancreases. 
Islet preparations from these species were often >90% pure, and 
>90% viable, as assessed by light refraction and vital dye exclu-
sion. Furthermore, in vitro islets of all species functioned well 
during perifusion as well post-transplantation even after several 
weeks in low temperature culture or after cryopreservation/thaw.
(2) Delivery of isolated islets to an easily accessible quasi-pan-
creatic site. Soon after the first successful high yield isolations 
from rodent pancreases, Ballinger, Scharp and Lacy57 began 
their heroic efforts of transplanting small quantities of islets into 
a variety of sites: under the capsule of kidney; under the capsule 
of spleen; intra-peritoneally, on the omentum; and later even 
the vision of islet transplantation. “I’m a simple pathologist; I 
believe what I can see and touch.” (Paul Lacy, September 1987). 
That’s how Lacy began describing the concept of islet function 
that guided his work in our first extended conversation in 1987. 
Admitting it didn’t encompass all that was known about islets, 
he thought it was fairly simple and utilitarian: “good for a prac-
ticing pathologist and would-be transplanter.”
Lacy conceived of islets of Langerhans as microperfused and 
autonomically innervated micro-organs containing at least three 
different types of endocrine cells each intercommunicating 
via intimate contacts and internal vasculature; this idea would 
later be called by Pipeleers “the bio-sociology of the islet”.48 
However, Lacy saw the b-cell as the key cell in the islet because 
its hypoglycemia-inducing secretion, insulin, unlike the a-cell’s 
hyperglycemia-inducing secretion, glucagon, could not be dupli-
cated by any other hormone (such as adrenaline). Lacy was 
convinced that the b-cell’s unusual biphasic response to a sus-
tained rise in glucose was critical to its function. An early spike 
of insulin secretion, lasting 5–10 minutes, from a small pool 
of “emiocytosis-ready” insulin granules, was critical in saturat-
ing insulin receptors in liver and causing a decrease in glucose 
release from, and increase in glucose entry into that depot store. 
An ever increasing second or dome phase of insulin release, last-
ing up to hours, from a more slowly mobilized pool of maturing 
insulin granules, traveling along microtubules to the vicinity of 
plasma membrane surface49,50 was critical for steady state glucose 
uptake into muscle and fat. He recognized that insulin secretion 
was primed by the digestive tract via both a vagal reflex and 
endocrine secretions from gut lining. However, since biphasic 
secretion was preserved after islets were isolated into a dener-
vated, non-perfused state and even after they had spread out into 
a monolayer in culture, Lacy conjectured that from a practical 
standpoint, if an islet were in a “safe, well perifused place” inner-
vation, incretin priming and even intact internal capillary beds 
might not be essential for the maintenance of an intrinsic secre-
tory pattern.
Lacy saw islets and islet cells as “plastic” rather than static tis-
sue. Over their extended function, islets would need to expand 
during developmental demand for increased insulin output (e.g., 
pregnancy) probably through hypertrophy. Also being a tissue 
with high metabolic turnover, some cells would get worn-out 
and need to be replaced with new ones, probably through the 
infrequent mitoses of the healthiest cells.51 In fact, in experi-
mental diabetes produced by partial pancreatectomy of the 
growing rodents, symptomatic disease only developed after the 
need for insulin outstripped the ability of the remnant hyper-
trophic islets to secrete it in a hyperglycemic environment.52,53 
In contemporary parlance this is now called “functional islet 
reserve”.54 Hence, protecting the function of islets on a long-
term basis required a sufficient complement of functioning islets 
to maintain near physiological circulating glucose and prevent 
the exposure of islets to prolonged hyperglycemia. However, 
he saw no reason why these processes would not occur even in 
environments foreign to islets provided the islets were in contact 
with the bloodstream and remained metabolically intact.
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capillary endothelial cells. His approaches, including extended 
culture of islets at subphysiological temperatures and/or high 
oxygen tension, treatment with anti-dendritic cell antibody as 
well as islet cryopreservation and thaw were not only seminal in 
islet transplantation but also in raising general “immunological 
consciousness” about dendritic cells. Currently, making donor 
islets less immunogenic and recipients less reactive remains a 
field of active bench-to-bedside inquiry.62
Part II: The Practice of Islet Transplantation 
to Cure Diabetes
The experience of the first 20 years. The proof of practicality 
of all great visions resides in the details of the success of wide-
ranging daily application. Concerning islet transplantation, 
Lacy, ever the ebullient public enthusiast, remained the private 
cool-headed realist. He knew that rodent “diabetes” was not 
human diabetes mellitus and believed that the transition of islet 
transplant from short lived, inbreed caged rodent to long-lived, 
free ranging and genetically diverse man would be difficult. 
However, he also freely admitted that the only way to investigate 
and circumvent the shortcomings of human islet transplantation 
was to perform the “in vivo” human experiments and take what 
was learned at the bedside back to bench for improvement. In 
addition he noted that “what’s worth doing never comes easy.” 
Nevertheless, by the late 1980s, a little over a decade after he 
authored a master plan for clinical islet transplantation,63 Lacy 
supervised the first partially successful transplantation.
By infusing, via an umbilical vein catheter, 800,000 nearly 
pure islets, harvested from 1.4 pancreata of brain dead patients, 
into the portal vein of an insulin-dependent diabetic renal 
transplant patient, already immunosuppressed with low doses of 
cyclosporine and prednisone, his team succeeded in maintaining 
the patient off exogenous insulin for 12 days.64 Within months, 
protégés, such as Ricordi, achieved more long term success with 
larger infusions of islets into other renal transplant patients 
treated with a steroid-free immunosuppression regime based on 
tacrolimus. In spite of the continuing dearth of tissue supply and 
the need for immunosuppression, the arduous race for the cure 
was on. Spurred by bursts of euphoria, especially one engendered 
by the “Edmonton protocol” utilizing sirolimus + tacrolimus-
based, steroid-free maintenance immunosuppression occurred. 
Repeated infusions of a pancreas’ worth of freshly isolated islets 
to brittle (hypoglycemia-prone) insulin dependent type 1 dia-
betics (DM 1) without renal allografts,65 were also attempted. 
To date, nearly a thousand patients have been transplanted with 
varying success using variants of the techniques presented the 
seminal paper by the Lacy team. We shall review this limited 
success, the clues these surgical “experiments” have offered us 
about engrafting islets, and how the return from bedside back 
to bench has allowed valuable clues to be tested individually and 
rigorously.
The most active islet transplantation centers (Edmonton, 
Miami, Minnesota and an international consortium) have 
reviewed their results after adoption of the Edmonton protocol 
now including daclizumab induction.66-68 Transplanted patients 
intratesticularly.58 The first experiments, in which islets were 
placed under the capsule of the kidney, demonstrated “proof of 
principle” that islets could secrete insulin and restore glycemia to 
syngeneic rats treated with streptozotocin, a b-cell specific toxin.
While technically a 2–3 ml volume of packed islets, obtained 
from a human donor, would easily be accommodated under 
the capsule of a single human kidney, practically subcapsu-
lar implantation required major surgery. Hence a less invasive 
approach to clinical islet transplantation was desirable. In addi-
tion, Lacy realized that insulin secretion into a site where first 
phase release would affect early uptake of glucose by liver was 
highly desirable from a physiological standpoint.
In 1973 Ballinger, Scharp and Lacy first reported the re-
establishment of near euglycemia and normal fasting insu-
linemia in streptozotocin-treated rats by injection/embolization 
of 400–600 hand picked, syngeneic islets in the portal vein, 
where glucose-avid hepatocytes would have primary access to 
glucose for rapid deposition as glycogen. Furthermore, within 
2–12 weeks, polyuria, polydypsia and hyperglycemia were abol-
ished and thereafter islets sustained their function for many 
months. Histological, long term transplanted islets (>5 months) 
contained well granulated a-, b- and d-cells that projected 
across the vascular space formed and formed direct contacts and 
even functional complexes with hepatocytes.59 In fact, neighbor-
ing hepatocytes showed increased glycogen and lipid deposits. 
(Quite recently this finding has been shown to have clinical 
implications in that in human patients who have received infu-
sion of islets into the portal vein, the delayed development of 
regions of hepatic steatosis has been used to track the presence 
of functional islets.60) By the mid-1980s clinical interventional 
radiology was nearly ready to tackle tissue infusions into human 
portal veins. However, the key piece of data missing from all 
of the islet transplantation trials in animals, and only provided 
years later,61 was a detailed study of the metabolic state of the 
transplanted islets, including their oxygen consumption, and 
their abilities to undergo biphasic insulin secretion and to revas-
cularize. As discussed below, this turned out to be truly critical 
issue in the preparation and survival of islet transplants.
(3) Making islets non-immunogenic. In early rodent experi-
ments, transplantation was performed syngeneically (between 
genetically identical individuals) or into a host with little capac-
ity for transplant rejection. To further reduce the probability of 
rejection a single does of anti-lymphocyte serum or monoclonal 
antibody was infused into the host prior to transplant. However, 
for transplantation into a non-immunocompromised host of non-
identical genetic background, either islets had to be rendered 
non-immunogenic or clinical immunosuppression would be 
needed. Lacy’s vision did not include chronic immunosuppres-
sion because he was fully cognizant of the vast array of systemic 
side-effects of contemporary immunosuppressants as well as their 
potential for very specific effects on islet metabolism. Lacy was 
convinced that “islets, as metabolic factories, won’t thrive with 
high doses of catabolic drugs like corticosteroids nearby”.
Lacy spent much of the 1980s developing approaches to 
reduce islet immunogenicity by attempting to deplete iso-
lated islets of dendritic macrophages (DC/MΦs) and remnant 
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drug treatment of recipients to reduce memory T cells prevent 
expansion of anti-islet autoreactivity?
What islet transplantation has further taught us about the 
islet as a micro-organ. Islet transplantation is still “a work in 
progress.”70,71 In retrospect, the overwhelming concern with 
obtaining sufficient islet mass for transplantation had caused 
“myopia” in the early transplant vision. On the one hand, there 
was a general lack of intimate knowledge and standardization 
of the metabolic state of islets being produced from the source 
pancreases and then transplanted after variable time in culture. 
On the other hand, there was little understanding of the stabil-
ity of the islets as micro-organs outside of their physiological 
milieu and especially in the portal vein. For example, tradition-
ally there was nearly universal reliance on optical measures for 
quantitation immediate “viability,” loose standards for quantita-
tion of yield (the islet equivalent), and, at best, modest stan-
dards for effective “in vitro” secretion after acute culture (2- to 
3-fold increases vs. >10-fold increase in the best quality islets). 
All of this led to the acceptance of mediocre quality tissue for 
transplantation. With the US Food and Drug Administration 
demanding quality assurance and standardization of the trans-
plant “product or device” prior to its infusion, these features 
are now under active scrutiny from both the retrospective and 
prospective point of view. The condition of the pre-transplant 
islet and its dependence on the quality of the source pancreas as 
well as the treatment of islets during and after harvest are now 
tracked by every transplantation center.
In the case of the pre-transplant islet, first it was neces-
sary to understand pre-harvest, which source of pancreases are 
most likely to prove the best tissue sources. Variables include 
donor age, adiposity, insulin reserve, and potential injury in 
the immediate pre-harvest state (e.g., during cytokine storm 
with brainstem death). There is general recognition of a central 
conundrum in islet harvestment: islets from the pancreases of 
young (<35) and lean donors, likely to be the most robust islets, 
are technically difficult to isolate, while those from pancreases of 
older (>50) and obese donors are somewhat larger and easier to 
liberate. Second, it was critical to minimize cold ischemia time of 
the pancreas both pre- and post-isolation. While islets are highly 
metabolic and do poorly under hypoxia, pancreases used for islet 
preparations are very often “left over” organs, offered for har-
vesting after of heart, kidneys and lungs have been obtained or 
after the pancreas has been rejected for whole organ transplan-
tation. Cold ischemia time is often well beyond an optimum 
of 6–8 hours. Recent improvements include the use of oxygen-
ated fluorocarbon solution transport. Moreover, the potency of, 
and exposure time to, enzymes in the islet isolation solutions, 
needed to be standardized and insured. Lastly, beyond the gen-
eral consideration of whether the best islet products are shaggy 
vs. round and nearly fresh vs. cultured for several days, there 
was a critical need for individual aliquots of islets to be carefully 
evaluated and standardized prior to transplantation. Advances, 
which may prove critical to the standardizing harvested islets, 
are the rapid use of laser scanning cytometry and measurement 
of O
2
 consumption on exposure to glucose to characterize islets, 
fluorescent-activated sorting of islet cells and optical assay of 
as a group had DM 1 for an average of 25 years, were of near 
ideal weight, had at least 50% normal creatinine clearance and 
experienced recurrent, severe hypoglycemia. Pancreases used as 
tissue sources were generally selected for cold ischemia time of 
less than 12 hours. The initial transplants consisted of 400,000 
islet equivalents (IE) (∼5–10 cc of tissue of 30–90% islet purity), 
either freshly prepared or cultured for 24–72 hours, and deter-
mined to be both bacteria- and endotoxin-free. Transplantation 
was achieved by percutaneous transhepatic intraportal infusion 
of a small volume of heparinized solution. Up to two booster 
infusions were later given bringing the average cumulative total 
to 800,000 IE.
While 44–82% of patients were insulin independent at the 
end of the first year, only 7.5% remained so at the end of the 
fifth year, despite apparent 80% graft survival as determined by 
C-peptide secretion. Never-the-less, patients returning to insu-
lin dependence had better glycemic control (HbA1c 7 vs. 9) with 
fewer episodes of hypoglycemia, the latter due to either reduced 
insulin requirement, improved glucose counter-regulation or 
some correction of symptomatic awareness of hypoglycemia. 
Chronic complications in transplanted patients included mouth 
ulcers, anemia, diarrhea, ovarian cysts, acne and increased need 
for treatment with antihypertensives and cholesterol lowering 
statin drugs. In addition, there were tendencies towards worsen-
ing of renal function and development of proteinuria, perhaps 
as a result of the immunosuppressive drugs used in the face of 
underlying diabetic glomerulosclerosis. Also, development of de 
novo donor specific antibodies in patients on continued immu-
nosuppression, raised concerns about possible predisposition 
to worsened outcomes in subsequent major organ transplants. 
In spite of case reports (reviewed in reference 69) there are no 
controlled studies to indicate whether islet transplantation slows 
progression of long-term systemic complications of DM such as 
cardiomyopathy, macro- or micro-angiopathy, proliferative reti-
nopathy, or peripheral/autonomic neuropathy. Hence results to 
date have caused some to question whether islet transplantation 
is ready for “prime-time” or just remains experimental and prop-
erly reserved as adjunctive therapy to renal transplantation in 
brittle diabetics with end-stage renal disease.
More fundamentally, the rapid declines in islet function 
post-transplant have caused even the key enthusiasts to re-
examine the original vision more critically. However, as with 
all important new therapies, severe challenges tend to provoke 
useful responses. In the case of islet transplantation, perhaps 
the most intriguing challenge is the issue of whether, as Lacy 
had originally speculated, immunosuppression, might be 
the true limiting step or Achilles’ heal of the entire process. 
Specifically, recent data suggest that in test organisms (and 
perhaps patients) with a history of autoimmune DM, T cell 
depletion produced by immunosuppressives such as FK and 
rapamycin might indirectly result in the homeostatic expan-
sion of the remaining T-cells, such as those autoreactive to 
the b-cell, and thereby cause a recrudescence of autoimmune 
DM, now however masquerading as transplant failure. If so, 
should patients be specifically chosen for lack of recurrent or 
recent autoimmunity? Alternatively, would pre- or concurrent 
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and leukocyte infiltration of islets. In addition, hepatocyte and 
produces Kupffer cell activation and damages islet cells via 
INOS and cyclooxygenase 2 generation, even in absence of portal 
thrombosis. There is encouraging evidence that this reaction may 
be inhibited, among other ways, by preincubation or co-admin-
istration with nicotinamide and inactivated TFVIIa and or by 
coating islets with autologous endothelial cells (obtained from 
peripheral venous scrapings and expanded in vitro to coat islets).
(4) Rapid onset of apoptosis may be induced by several fac-
tors. The combination of IBMIR and apoptosis may produce loss 
of 70% of infused islet tissue in 3 days. Here again, genetic and 
pharmacological inhibition has been possible in the forms of ex 
vivo transduction of islets with X-linked inhibitor of apoptosis 
(repressor of terminal caspase pathway).
(5) Functional revascularization and its maintenance. Data 
from rodents suggests that long term, even under the best condi-
tions in syngeneic rodents, less than 75% of transplanted islets 
remain intact. Islets retrieved from any engrafted site displayed 
decrease oxidative utilization of glucose, decreased insulin con-
tents, and decreased regulated insulin release. However, intra-
pancreatically-transplanted islets seem to suffer the least while 
intraportally-infused islets seem to suffer the most.75 Islets recov-
ered after intra-portal infusion often have poorly perfused cores, 
with intra-islet pO
2
 being 5–10 torr after implantation into the 
portal vein vs. 40 torr in the intact pancreas.76 Tissue hypoxia 
mitochondrial membrane potential in product b-cells, and rapid 
assessment of insulin release by single islets using microfluidic 
perfusion chambers and secretion assays other than the very time 
consuming radio-immunoassay.
In the case of the transplanted islets, especially ones introduced 
into the portal vein, their post-transplant courses appear far from 
smooth. Following Paul Robertson’s apt description, there is 
increasing evidence that the islet in the portal vein is a “stranger 
in a strange land” and suffers on a number of accounts (see 
Fig. 3). However, increasing recognition of key issues has stimu-
lated a variety of approaches to ameliorating some of them.
(1) Ischemic damage during procurement or culture results 
in an initial dearth of functional islets; a conservative estimate 
is that 30% of islets have necrotic cores at the time of infusion.
(2) Immediate islet loss due to coagulation induced by tis-
sue factors resulting from islet prep impurities (acinar and duct 
fragments) or portal vein thrombosis resulting from vessel injury 
during infusion.72,73
(3) Ongoing loss of 30–40% of viable islets after introduction 
into the portal vein, even in the absence of portal thrombosis. 
An instant blood-mediated inflammatory/thrombotic reaction 
(IBMIR) has been identified,74 where stress + hypoxia-induced 
surface and soluble tissue factor, a cytokine receptor subfamily, 
results in expression of FVIIa, and macrophage chemoattractant 
factor. This results in platelet coagulation, complement activation 
Figure 3. Complexities and hidden pitfalls inherent in islet transplantation, especially into the portal circulation. (A) The islet’s sheltered, nurtured 
existence in its native environment, where its intrinsic microcirculation is intact, its portal circulation allows it to increase its blood flow by borrowing 
from acinar supply post-prandially, and its intrinsic replenished with cells or replacement as a micro-organ, when worn out. (B) The islet’s precarious 
situation as a “stranger” post-transplantation (see text box legend).
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Glucagon secretion in response to arginine, but not to hypoglyce-
mia, is also well preserved.80 From this experience, as predicted by 
Lacy, the functional quantity of transplant mass is critical to its 
subsequent success and, as suggested by the islet transplantation 
studies, the portal circulation might be less than ideal for stable 
counter-regulatory function in glucose control. Surprisingly, 
in light of Lacy’s reduced model of islet function, the mass of 
co-transplanted acinar and ductal tissues did not seem to be an 
impediment to subsequent islet function. Perhaps the trade-off 
point, between the trauma of islet purification and the avoidance 
of potential for tissue inflammatory response by less extensive 
purification of islets, needs to be shifted. As suggested by tissue 
culture studies, including those of pancreatic discards after islet 
isolation,81,82 cells within fragments of ductal and acinar tissue 
liberated from their restraining matrix, might actually trans-
differentiate and bud off islets, or else secrete factors that protect 
islets or enhance their revascularization during hyperglycemia. 
Interestingly, when the Edmonton group carefully compiled the 
characteristics of infused islet tissue and compared this with the 
survival of the subsequent transplant, after two years transplan-
tation they found a significant positive correlation between the 
function of the intra-portally administered allografts and the 
number of ductal (cytokeratin-19 positive) cells in the infusate. 
In the same study, optical estimates of islet purity did not cor-
relate well with insulin staining of tissue and long-term outcome 
of graft did not correlate well with post-isolation in vitro glucose-
induced insulin secretion.
Second, despite the feared arduousness of the procedure, 
beginning in the 1990s pancreas transplantation became gen-
erally successful. New techniques for organ harvesting reduced 
exocrine damage; bladder drainage of ductal secretions per-
mitted easy of assessment of amylase secretion as an index of 
exocrine function; subsequent enteric drainage avoided compli-
cations of intermittent metabolic acidosis and volume depletion; 
and improved HLA matching and immunosuppressive regimes 
(based on tacrolimus, rather cyclosporine), improved graft sur-
vival.83 Simultaneous renal/pancreatic transplantation had three-
year survival rate of 70–80%, or similar to most other types of 
organ transplantation, and provided a means of effective con-
trol of glycemia and autonomic insufficiency. Solitary pancreatic 
transplantation could reverse lesions of diabetic nephropathy and 
as well as macro-vascular changes. In this case Lacy may have 
been too pessimistic: in the face of well-preserved islet mass and 
adequate attachment to central vascular supply, a limited degree 
of chronic rejection and cytotoxicity from immunosuppressant 
therapy may not be as swift and potent islet killer as he suspected.
Part III: Looking Over the Horizon at Emerging 
Alternative Approaches and Perspectives 
on the Roads not Taken
My second extended conversation with Lacy occurred in 2000 
in one of his visits to Washington University after his retire-
ment from active scientific inquiry. Lacy was now the thoughtful 
contributor to advisory boards in academia and industry and 
an elder statesman in the ever expanding diabetes community. 
may acutely raise cytosolic [Ca2+] and contribute to constitui-
tive insulin release, while decreasing glucose-induced insulin 
release, which requires vigorous aerobic, including mitochon-
drial, metabolism. Moreover, long-term this hypoxia may be 
detrimental to survival of b-cells predisposing them to stress-
induced apoptosis, especially as b-cells lack a hypoglycemia/
hypoxia inducible mitochondrial inner membrane protein that 
protects other cells that rapidly oxidize glucose, such as neigh-
boring a-cells and cardiac myocytes.77 In humans and non-
human primates, islets introduced into the portal circulation 
become enveloped in thrombus and then are slowly incorpo-
rated subendothelially in the vessel wall to be revascularized by 
the vaso-vasorum.75 This long term revascularization, achieved 
by an arduous, islet-threatening process, is likely to be subop-
timal, in spite of evidence that islets secrete angiogenic factors, 
such as vascular endothelial cell growth factor-A (VEGF-A) 
and angiopoietin-1. Two novel approaches focusing on improv-
ing the islet vascularization are being developed. The first is 
based on tissue engineering and consists of co-culture of islets 
with bone marrow derived mesangial stem cells and endothe-
lial cells to provide adequate source of angiogenic factors as 
well as promote invasion of endothelial cells and the sprouting 
of chimeric vessels from the islet. The second is pre-transplant 
treatment of islets with prolactin, a known angiogenic stimulant 
to islets.78
(6) Loss of neural innervation prevents the neurally-mediated 
increase in islet perfusion during increased oxygen demand of 
glucose utilization occurring with stimulus-secretion coupling. 
This is likely not reversible given the geography of transplanted 
islets.
(7) Poor islet cell proliferation combined with unlikely islet 
neogenesis should militate replacement of apoptotic b-cells and 
result in progressive decline in the number of functional islets. 
Clinically, attempts at slowing apoptosis and promoting islet 
neogenesis in patients with chronic allograft dysfunction have 
included administering exenatide, a long-acting analog of GLP-1.
In the future magnetic resonance imging, now being devel-
oped with targeted iron oxide “contrast agents” for use in rodents, 
may permit monitoring of islet engraftment and vascularization, 
immune rejection, glucotoxicity and the role of islet purity in 
ultimate longevity, thereby helping to evaluate current, as well as 
predict future, allograft function.79
What auto-transplantation of partially purified islets and 
whole pancreas transplant have taught us about the islet as a 
micro-organ. In addition, valuable lessons have been learned 
about the viability of the islet as a micro-organ when the results 
of transplantation of purified islets are compared with two other 
replacement techniques. They are (1) auto transplantation of 
pancreatic tissue, in patients with chronic pancreatitis and (2) 
simultaneous renal pancreatic transplantation, in diabetics with 
renal failure two competitor islet replacement techniques. First, 
from the experience of the Robertson’s group it is clear that rap-
idly prepared, partially purified islet harvests autotransplanted 
into the portal vein can provide of reduction in fasting glucose 
for as long as 13 years. Here reduction in glycosylated hemo-
globin is highly correlated with the mass of initial islet infused. 
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variety of pathogens difficult to test for, wide fluctuations in 
pre-harvest organ perfusion and the possible effects intravas-
cular coagulation causing micro-angiopathy. The issue of islet 
xenoimmunology and transplantation might be addressed (1) 
by genetic engineering to produce organs that minimize host 
immune or (2) by “immunoisolation” of transplanted tissues. 
“Knock out the enzymes that trigger reactions or surround the 
islets with a semi-permeable membrane giving them access to 
nutrients but not antibodies or immune cells. Then hopefully 
they will secrete small molecules like insulin and not be a source 
of retrovirus or oncogenes.” Currently, it is possible knock out of 
a 1,3 galactosyltransferase,85 an antigen responsible for antibody 
response and to engineer inhibitors of the complement system 
cascade. Lacy was enthusiastic about encapsulation of islets in 
a selectively permeable matrix.88,89 “With introduction into the 
peritoneal cavity, they could even be retrieved and exchanged 
for new ones if they simply wore out.” The major question in his 
mind was whether to use embryonic, foetal, neonatal or young 
or adult pigs as islet sources. Lacy’s new vision of islet trans-
plantation was actually addressing two “brave new world” areas, 
xenotransplantation and encapsulation, which have gained 
increasing interest of the past decade.
In the early 1990s, Lacy and Scharp,90 along with similarly-
minded investigators, had begun work on islet encapsulation. 
Since the mid-1990s, individually encapsulated islets (in micro-
spheres) or small clusters of encapsulated islets (in cylindrical 
diffusion capsules) had been introduced free into the blood-
stream or into the peritoneal cavity. Since then, islets have also 
been seeded onto hollow fiber semi-permeable membranes to 
form a bio-hybrid device resembling a modern dialyzer and 
perfused as an arteriovenous shunt.89 Generally, the encapsu-
lating medium has consisted of a biocompatible alginate whose 
surface is cross-linked with calcium to form capsules that are 
then coated with poly-L-lysine (PLL). Key problems using this 
approach have been loss of islet function and continuing need 
for immunosuppression, two likely related phenomena. Over 
time, the beads often collapse, and the PLL permits growth of 
fibroblasts attracting CD4+ T cells, B cells and macrophages and 
causing the accumulation of cytokines, chemokines, comple-
ment and immunoglobulins, all of which impair function of the 
encapsulated islets.91 While implantation of these capsules has 
improved glucose control in animal studies, it often proved dif-
ficult to demonstrate significant insulin secretion by retrieved 
beads. However, there has been recent good news in the form of 
better understanding of why encapsulated islets are poor secre-
tors as well as the design of better beads.
Transplantation of porcine islets in the absence of encapsula-
tion has also been examined, with resultant reports of prolonged 
reversal of diabetes reported in non-human primates after intra-
portal infusion of either adult or neonatal porcine islets.92,93 
While heavy immunosuppressive targeting of T cells was used 
to delay eventual T-cell mediated rejection, genetic engineer-
ing to eliminate hyper-acute rejection of solid organs, was not 
attempted. The ability to make pig transgenics, however, sug-
gests that IBMIR might be “engineered away”. The issue of the 
relative advantage of neonatal vs. adult islets remains: while 
His views were much more philosophical. As far as curing dia-
betes by islet transplantation, he realized that several limiting 
problems had emerged. These included the likely insurmount-
able problem of scarcity of human tissue; the vagaries of immu-
nology and immunosuppression; and the nagging complexity of 
transplanting this “simple” micro-organ, including whether the 
portal vein was an ideal target site. While he had considered 
alternative sites for transplantation, including intraperitoneal 
(omental) and even intramuscular, paralleling its increasingly 
use for parathyroid transplantation, he was more concerned 
that realistically transplantation would probably require a new 
approach: use of encapsulated surrogate islet tissue. However, 
he voiced a more fundamental concern: over the length of his 
career the scope of diabetes had changed from an autoimmune 
disease of a few immunologically unfortunate individuals into 
an environmentally induced epidemic of over-calorization in a 
sedentary population,84 an impending public health catastrophe 
that no program of islet replacement would effectively serve. Put 
another way, in 50 years, the bad genetic background underlying 
the bulk of diabetes had shifted from the tendency toward auto-
immunity, which always made life miserable, to the tendency 
towards metabolic thriftiness, which in the past undoubtedly 
had a clear selection advantage. Though in no way discounting 
DM 1 as a major disease, Lacy wondered how drastically differ-
ent his career in diabetes research would be if he were starting 
out in 2000. Would he largely be investigating how to prevent 
islet toxicity due to chronic, excessive nutrient fuel rather than 
trying to replace islet function? To conclude this tribute we shall 
refer to some of Lacy’s thoughts, as well as recent developments, 
concerning these areas.
Identifying a surrogate transplant tissue for an alternative 
transplantation approach. If not human islets for transplanta-
tion, what then? As we have emphasized, Lacy subscribed to the 
following working definition of b-cells: a cell population that 
(1) senses glucose over a physiological range of 3–7 mM and 
responds by secreting insulin, (2) interacts appropriately with 
glucagon-secreting a-cells and somatostatin-secreting d-cells 
and (3) regulates its own mass by precisely balancing of mitosis 
and apoptosis over years while still being capable of undergo-
ing an occasionally growth spurt (such as in pregnancy). Hence 
b-cells could only be replaced by b-cells. If scarcity of human 
tissue was the critical issue, this could be circumvented with 
xenotransplantation using stable islets from pigs, which are 
long-lived organisms with lower sensitivity to destruction by 
autoimmunity85,86 and whose insulin, differing from human by 
only 1 amino acid, had been successfully used to treat diabetics 
for decades. At this time he preferred xenotransplantation to de 
novo tissue engineering using transformed clonal cell lines or 
elaborated stem cells and perhaps even to tissue extracted from 
life-support brain dead humans. Specifically he thought that 
pigs could be raised in a sterile environment (now in develop-
ment in Minnesota and New Zealand), screened and genetically 
modified to reduce risks of xeno-zoonosis.87 The ability to har-
vest pancreases from health animals rather than life-supported 
cadavers would substantially reduce the problems of using isch-
emic, cytokine-activated tissue likely exposed pre-harvest to a 
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these cells are not well regulated. In the second case, the tran-
scription factors are NGn3, Pdx1 and Mafa.
Lastly, he’d likely give a critical eye to a recently reported 
conditionally transformed (reversibly immortalized) non-
tumorigenic human b-cell clone (NAKT-15). These reverted 
cells display a large complement of insulin granules, hormone 
processing enzymes and b-cell transcription factors (e.g., Pdx-1) 
as well as impressive increases in insulin and C-peptide secre-
tion in response to 25 mM glucose, and control blood glucose 
for up to 30 weeks in combined immunodeficient mice made 
diabetic with streptozotocin.101 One might almost here Lacy say 
that we’re not there yet, but a little closer.102
Interrupting islet gluco-and lipo-toxicity and prevention of 
type 2 DM. In the 1990s the previously vague issue of glucotox-
icity, which Lacy and his endocrinology colleague David Kipnis 
recognized in the 1960s, started to be more clearly objectified. 
While short periods (few hours) of hyperglycemia may be stimu-
lus for b-cell mitosis and neogenesis, prolonged hyperglycemia 
has an opposite effect.101 Several lines of experiments revealed 
that islets incubated with even twice normal glucose concentra-
tion (11 mM) for as little as one week showed increased rates of 
insulin release at low (1.7–3 mM) glucose yet failed to increase 
their secretion further at elevated (16.7 mM) glucose, despite 
having adequate insulin stores and pro-insulin synthesis and 
hyperglycemia-induced increases in glucose oxidation.103 b-cells 
had “tuned out” to glucose, but why? The situation was clearly 
worsened by incubation with 28 mM glucose, where insulin 
synthesis was massively downregulated. More recent data sug-
gest that in partially pancreatectomized rats with elevated serum 
glucose concentrations, b-cells in remnant islets actually dedif-
ferentiate and lose mRNA coding for most of the proteins in the 
cascade for glucose signaling. Surprisingly, they also upregulate 
mRNA coding for anti-oxidant and anti-apoptotic processes 
(e.g., glutathione peroxidase, superoxide dismutase and cata-
lase), which are normally present at quite low levels, and they 
are partially protected against corticosteroid-induced apop-
tosis.104 In a sense, this may represent a balance state of “don’t 
overuse it and don’t rapidly loose it.” Islets need this protection 
as hyperglycemia, per se, may cause b-cell damage. Prolonged 
exposure to elevated glucose may result, among other features, in 
(1) secretion of cytokines, such as IL-1γ that induce nitric oxide 
synthetase and the production of nitric oxide, which is toxic to 
b-cells, probably by inducing both apoptosis and an inflamma-
tory response; and (2) over-synthesis of pro-insulin to be traf-
ficked through the endoplasmic reticulum (ER) resulting in “ER 
stress.”105
With this as a basis, attempts have been made in experimen-
tal models to protect b-cells from toxicity and potentially reverse 
diabetes.106,107 These include rendering patients truly euglycemic 
by insulin therapy (as opposed to glucose control by an oral hypo-
glycemic agent or a peripheral insulin sensitizer); administra-
tion of long-acting analogs of glucagon-like peptide 1 (GLP-1), 
which in addition to enhancing glucose-induced insulin release 
also appears to stimulate b-cell proliferation and inhibit apop-
tosis; and/or administration of a natural soluble IL-1 receptor 
antagonist, IL-1Ra. Other approaches include administration of 
neonatal islets do not function immediately, they are less immu-
nogenic and have potential for growth. Encouragingly, thus far 
no transmission of porcine endogenous retroviruses has been 
reported.
Finally I took the risk and asked about his views of the then 
developing research with cell based therapies for b-cell replace-
ment: engineered clonal b-cells or harvesting/differentiating 
stem cells to be b-cell-like. His responses were bits of wry skep-
ticism delivered in a mildly irritated tone. First, he asked how 
trustable one might expect a tumor cell to be regarding slow 
reproduction and stably secretion vs. reversion to uncontrolled 
proliferation and unpredictable or episodic secretion. Second, 
he asked how one would actually identify the stem cell for an 
adult b-cell and if one started far back in development would 
one simply be growing foregut teratomas for “a heck of a long 
time before figuring anything out.”
However, over the past ten years substantial progress has been 
made on harvesting/differentiating/engineering b-cell-like enti-
ties. While I’d anticipate Lacy would still have a healthy skepti-
cism regarding these endeavors, he’d probably maintain a real 
interest in them. Certainly, he’d be very pleased to learn of new 
evidence supporting his contention that the best way to replace a 
b-cell is with another real b-cell. Based on genetic linkage trac-
ing analysis, the major source for steady state b-cell replacement 
as well as proliferation after partial pancreatectomy, or targeted 
ablation is from extant ones by simple cell division. Furthermore, 
it is now proposed that cell division is the source of islet mass 
expansion in pregnancy, after gastric bypass surgery, and per-
haps in partial reversal/recovery from autoimmune diabetes.94,95 
Unfortunately, it has also become clearer that currently used 
immunosuppressive drugs inhibit regenerative restoration of 
reduced b-cell mass by cell division. However, being an astute 
biologist, he’d likely anticipate that there is still some room for 
a facultative endocrine progenitor cell in the adult pancreas. 
With partial pancreatic duct ligation causing acinar degenera-
tion and duct proliferation, cells expressing the transcription 
factor neurogenin-3 (NGn3) can be harvested and then injected 
into explanted embryonic pancreas to differentiate into mature 
islet endocrine cells, recapitulating their role in the embryonic 
mode of endocrine pancreatic development.96-98 This would tend 
to downplay potential roles of bone marrow, spleen and liver 
as primary sources of stem cell for adult islet regeneration but 
suggest that going several steps back to attempting might not be 
entirely farfetched.99
Assuredly, he’d likely be interested in some tantalizing devel-
opments suggesting the possibilities of (1) differentiating an 
embryonic stem (i.e., pluripotential cells derived from the inner 
mass of the blastocyst) through a pancreatic endodermal stage, 
which then could be matured into pro-endocrine cells, and 
(2) reprogramming of adult pancreatic exocrine cells into b-cells 
by inducing the re-expression of several transcription factors.100 
In the first case, one such recent attempt has made use of an ini-
tial induction factor, activin A and culminated in the maturation 
of foregut-like tissue after several month of implantation/matu-
ration in mice made diabetic with streptozotocin. Improved gly-
cemic control was achieved, though C-peptide secretion from 
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subtle, is never treacherous.” This spirit has been transmitted to 
his long term scientific partner David Scharp and former post-
doc Camillo Ricordi who vigorously pursue Lacy’s vision of 
curative islet transplantation.
Lastly, Paul Lacy conducted his career with intellectual 
honesty, openness and generosity of spirit to colleagues with 
diverse interests in islet biology and immunology as well as to 
generation of medical student, whom he taught and inspired at 
Washington University. While studying the sometimes illusive 
islet, he personified an ethos of “no man is an island entire of 
himself.” That personal legacy may be as memorable as his sci-
entific one.
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anti-CD3 antibodies to halt autoimmune destruction and bone 
marrow engraftment at first detection of autoimmune DM.108 It 
is worth recalling that as the metabolic syndrome (or what we 
might call “hypertensive diabesity”) develops in glucotoxic indi-
viduals, dyslipidemia and b-cell lipotoxicity also occurs. The 
latter combination is what appears to be most injurious to islet-
sin that saturated fatty acids exert pro-apoptotic effects through 
production of ceramide that injures mitochondria while low 
density lipoproteins appear to be apoptosis-inducing through 
c-Jun N-terminal kinase. However, both glucotoxicity and lipo-
toxicity, if caught early, might be pharmacologically reversible as 
well as epidemiologically preventable.
Epilogue
Paul Lacy was a scientist with enormous drive and focused 
vision. When others asked “wherefore and how” he responded 
with an emphatic “why not,” and galvanized others to enthu-
siastically pursue practical answers with him. He seemed to be 
guided by the dictim of Albert Einstein that “nature, though 
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